As a start-up biopharmaceutical company, Zebra Pharmaceutical has received attention and support from various government departments, investment circles, and enthusiastic individuals from all walks of life in Zhongshan since its establishment. On behalf of the company's board of directors and all employees, I would like to express our gratitude to you. On January 9, 2025, Zebra Pharmaceutical (Zhongshan) Co., Ltd. held its first "Open Day" event. At the beginning of the event, the company's chairman Wen Xiaoyan expressed sincere thanks to the guests from all walks of life who came to participate.
Zebra Pharmaceutical Annual Keywords：Embark
When reviewing the development of the company in 2024, Dr. Wen Xiaoyan summarized the whole year with the word "sailing": at the end of May, the international first-class standard laboratory with an area of over a thousand square meters was successfully completed in just three months; In June, the "Zhongshan Biomedical Industry Forum and the 5th Zebrafish Precision Medicine Academic Conference" led by the company was successfully held, and more than 100 experts and scholars in the field of biomedicine from around the world were invited to attend; In July, the company had a direct conversation with the team of Cai Lei, former vice president of JD.com, who suffered from ALS, and both sides agreed to jointly promote the research and development of ALS drugs; In October, the company's CRO service project began operation and conducted commercial cooperation with related enterprises, research institutions, and hospitals; In November, multiple overseas talents recommended by the company once again received talent awards from the country and Guangdong Province; In December, the company's innovation and entrepreneurship team project received relevant awards from the Zhongshan Municipal Government. The successive achievements indicate that Zebra Pharmaceutical is steadily moving in the right direction.
Dr. Le Zhiyong, the CEO of the company, introduced the company's development plan for 2025 to the guests. He mentioned that the company will provide better choices for patients and doctors under the principles of "integrity, professionalism, collaboration, and innovation". The company plans to use 12-18 months to advance the research and development of two new drug pipelines into the preclinical stage; At the same time, we will increase our CRO service efforts, further promote the construction of precision medical service platforms and innovative service platforms, and create a stable revenue channel for the company.
During the interactive communication session, representatives from relevant government departments in Zhongshan expressed that the achievements of Zebra Pharmaceutical in 2024 are obvious to all. They hope that Zebra Pharmaceutical will continue to actively respond to the government's call this year, follow policy guidance, introduce more international talents, accelerate the development of new drug projects, and contribute greater strength to the economic development and biopharmaceutical industry in Zhongshan.
The representatives of the attending investors were also pleased with the research and development progress and talent introduction achievements of Zebra Pharmaceutical last year, and expressed their willingness to continue to pay attention to Zebra Pharmaceutical and increase investment cooperation with it at the appropriate time.
After the exchange event, the attending guests visited ZebraPeutics' zebrafish room and drug screening laboratory, witnessing the company's new drug research and development, CRO services, and quality control processes firsthand.
